Arjan Diepstra
dr.
As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.
Latest publications
(216)
Activities
(38)
Press/Media
(7)
Prizes
(4)
Datasets
(1)
Supervised work
(12)
Plasma vesicle-associated mirnas as therapy response biomarkers in hodgkin lymphom
D M. Pegtel, E. Drees, M. A. J. van Eijndhoven, N. J. Groenewegen, S. van Niele, R. Prins, S. R. Baglio, J.M. Zijlstra, H. van der Voorn, S. F. W. M. Libregts, M. H. Wauben, R. X. de Menezes, J. R. T. van Weering, R. Nieuwland, A. Diepstra, D. de Jong
Functional analysis to elucidate the susceptibility mechanisms of SNPs at the REL, GATA3 and TCF3 Loci in classical Hodgkin Lymphoma
Genome Wide Association Studies (GWAS) revealedsignificant associations for SNPs mapping at the REL, GATA3 andTCF3 loci with cHL susceptibility. In this study, we aim to elucidatethe susceptibility mechanism of these associations by establishingpossible expression quantitative trait loci (eQTL) effects. Methods.EQTL analysis was performed in EBV transformed lymphoblastoidcell lines (LCLs) generated from 96 controls and 70 former cHLpatients as well as in three previously published large gene expressionstudies of HRS cells and total HL tissue samples. Results. An eQTLeffect for REL was found using cHL total tissue array data...
Hodgkin Reed Sternberg cells in classical hodgkin lymphoma are surrounded by t regulary cells while lymphocyte predominant cells of nodular lymphocite predominant hodgkin lymphoma are surrounded by t follicular helper cell
Disturbed antigen presentation in classical Hodgkin Lymphoma; implications for immune checkpoint inhibitor therapy
Immune checkpoint inhibitors are being tested in clinical trials and show great promise in the treatment of classical Hodgkin lymphoma (cHL). The proposed mechanism of action of these inhibitors consists of reactivating T lymphocytes that have become unresponsive as a consequence of inhibitory mechanisms exerted by the tumor cells. These reactivated T cells are expected to kill tumor cells after recognizing tumor cell derived antigens that are presented by Human Leukocyte Antigens (HLA) at the tumor cell surface. Consequently, lack of tumor cell surface expression of HLA may...
M. Nijland, Lydia Visser, Rianne Veenstra, K. Kushekhar, G. van Imhoff, Anke Berg, van den, A. Diepstra
The Phenotype of Macrophages in the Inflamed Vascular Wall of Giant Cell Arteritis Resembles the Phenotype of Non-Classical Monocytes